DE69619125T2 - Amino substituierte pyrimidinen und triazinen - Google Patents

Amino substituierte pyrimidinen und triazinen

Info

Publication number
DE69619125T2
DE69619125T2 DE69619125T DE69619125T DE69619125T2 DE 69619125 T2 DE69619125 T2 DE 69619125T2 DE 69619125 T DE69619125 T DE 69619125T DE 69619125 T DE69619125 T DE 69619125T DE 69619125 T2 DE69619125 T2 DE 69619125T2
Authority
DE
Germany
Prior art keywords
alkyl
formula
compound
crf
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69619125T
Other languages
German (de)
English (en)
Other versions
DE69619125D1 (de
Inventor
R. Mccarthy
J. Moran
R. Webb
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Neurocrine Biosciences Inc
Original Assignee
Janssen Pharmaceutica NV
Neurocrine Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV, Neurocrine Biosciences Inc filed Critical Janssen Pharmaceutica NV
Publication of DE69619125D1 publication Critical patent/DE69619125D1/de
Application granted granted Critical
Publication of DE69619125T2 publication Critical patent/DE69619125T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32One oxygen, sulfur or nitrogen atom
    • C07D239/42One nitrogen atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48Two nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48Two nitrogen atoms
    • C07D239/49Two nitrogen atoms with an aralkyl radical, or substituted aralkyl radical, attached in position 5, e.g. trimethoprim
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D251/00Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/14Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)
DE69619125T 1995-10-17 1996-10-15 Amino substituierte pyrimidinen und triazinen Expired - Fee Related DE69619125T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US568795P 1995-10-17 1995-10-17
PCT/EP1996/004478 WO1997014684A1 (en) 1995-10-17 1996-10-15 Amino substituted pyrimidines and triazines

Publications (2)

Publication Number Publication Date
DE69619125D1 DE69619125D1 (de) 2002-03-21
DE69619125T2 true DE69619125T2 (de) 2002-09-26

Family

ID=21717189

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69619125T Expired - Fee Related DE69619125T2 (de) 1995-10-17 1996-10-15 Amino substituierte pyrimidinen und triazinen

Country Status (18)

Country Link
US (1) US6288060B1 (ko)
EP (1) EP0863882B1 (ko)
JP (1) JPH11513678A (ko)
KR (1) KR19990045744A (ko)
AR (1) AR004221A1 (ko)
AT (1) ATE212987T1 (ko)
AU (1) AU703096B2 (ko)
CA (1) CA2229710A1 (ko)
DE (1) DE69619125T2 (ko)
DK (1) DK0863882T3 (ko)
ES (1) ES2172681T3 (ko)
MY (1) MY113945A (ko)
NO (1) NO310771B1 (ko)
NZ (1) NZ320227A (ko)
PT (1) PT863882E (ko)
TW (1) TW378206B (ko)
WO (1) WO1997014684A1 (ko)
ZA (1) ZA968732B (ko)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6191131B1 (en) 1997-07-23 2001-02-20 Dupont Pharmaceuticals Company Azolo triazines and pyrimidines
US6313124B1 (en) 1997-07-23 2001-11-06 Dupont Pharmaceuticals Company Tetrazine bicyclic compounds
US6060478A (en) * 1996-07-24 2000-05-09 Dupont Pharmaceuticals Azolo triazines and pyrimidines
US6124289A (en) * 1996-07-24 2000-09-26 Dupont Pharmaceuticals Co. Azolo triazines and pyrimidines
US7094782B1 (en) 1996-07-24 2006-08-22 Bristol-Myers Squibb Company Azolo triazines and pyrimidines
DE19837387A1 (de) * 1998-08-18 2000-02-24 Aventis Res & Tech Gmbh & Co 3'-Desoxypentopyranosyl-Nucleinsäure, ihre Herstellung und Verwendung
AU3357700A (en) * 1999-02-16 2000-09-04 E.I. Du Pont De Nemours And Company Phenoxypyrimidine insecticides and acaricides
US6432989B1 (en) 1999-08-27 2002-08-13 Pfizer Inc Use of CRF antagonists to treat circadian rhythm disorders
US6506762B1 (en) 1999-09-30 2003-01-14 Neurogen Corporation Certain alkylene diamine-substituted heterocycles
US6525067B1 (en) * 1999-11-23 2003-02-25 Pfizer Inc Substituted heterocyclic derivatives
WO2001062718A1 (fr) * 2000-02-25 2001-08-30 Japan Tobacco, Inc. Dérivé de benzamide et utilisation de celui-ci
CA2416248A1 (en) 2000-07-18 2002-01-24 Neurogen Corporation 5-substituted 2-aryl-4-pyrimidinones
ATE283844T1 (de) 2000-09-19 2004-12-15 Sumitomo Chemical Co Pyrimidinverbindungen und deren verwendung als pestizide
HUP0303038A2 (hu) 2000-09-21 2003-12-29 Bristol-Myers Squibb Co. Szubsztituált azolszármazékok mint kortikotropin releasing faktor inhibitorok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
US20030055249A1 (en) * 2001-07-17 2003-03-20 Fick David B. Synthesis and methods of use of pyrimidine analogues and derivatives
US6872827B2 (en) * 2002-04-26 2005-03-29 Chembridge Research Laboratories, Inc. Somatostatin analogue compounds
EP1626725A4 (en) * 2003-05-29 2006-06-14 Synta Pharmaceuticals Corp Heterocyclic compounds for the prevention and treatment of disorders associated with excessive bone formation
US20060024661A1 (en) * 2003-07-30 2006-02-02 The Regents Of The University Of California Modulation of CRF potentiation of NMDA receptor currents via CRF receptor 2

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2595697B1 (fr) 1986-03-13 1988-07-08 Rousselot Cie Derives de benzyl-pyrimidine, leur procede de preparation ainsi que les compositions en contenant
FR2692893B1 (fr) 1992-06-24 1994-09-02 Sanofi Elf Dérivés alkylamino ramifiés du thiazole, leurs procédés de préparation et les compositions pharmaceutiques qui les contiennent.
WO1995010506A1 (en) * 1993-10-12 1995-04-20 The Du Pont Merck Pharmaceutical Company 1n-alkyl-n-arylpyrimidinamines and derivatives thereof
TW574214B (en) * 1994-06-08 2004-02-01 Pfizer Corticotropin releasing factor antagonists

Also Published As

Publication number Publication date
WO1997014684A1 (en) 1997-04-24
US6288060B1 (en) 2001-09-11
PT863882E (pt) 2002-07-31
EP0863882B1 (en) 2002-02-06
TW378206B (en) 2000-01-01
ATE212987T1 (de) 2002-02-15
AU7292996A (en) 1997-05-07
ZA968732B (en) 1998-04-16
DK0863882T3 (da) 2002-05-06
AR004221A1 (es) 1998-11-04
AU703096B2 (en) 1999-03-18
DE69619125D1 (de) 2002-03-21
EP0863882A1 (en) 1998-09-16
CA2229710A1 (en) 1997-04-24
NZ320227A (en) 1998-11-25
ES2172681T3 (es) 2002-10-01
JPH11513678A (ja) 1999-11-24
NO310771B1 (no) 2001-08-27
NO981623D0 (no) 1998-04-08
NO981623L (no) 1998-06-09
MY113945A (en) 2005-12-14
KR19990045744A (ko) 1999-06-25

Similar Documents

Publication Publication Date Title
DE69619125T2 (de) Amino substituierte pyrimidinen und triazinen
DE69708059T2 (de) Thiophenopyrimidine
DE69818248T2 (de) Chinolin- und chinazolin-derivate als crf antagonisten
DE69726724T2 (de) Tetrahydropteridine und pyridylpiperazine zur behandlung von neurologischen störungen
DE69736513T2 (de) Pyrazolopyrimidine als crf rezeptor-antagonisten
DE69926665T2 (de) Azolo-Pyrimidine
DE69735712T2 (de) Aryl-pyrimidin-derivate
DE69903333T2 (de) Crf rezeptor-antagonisten und darauf bezogene methoden
US6352990B1 (en) CRF receptor antagonists and methods relating thereto
DE60303238T2 (de) Pyrimidin-Essigsäure Derivate geeignet zur Behandlung von CRTH2-bedingten Krankheiten
DE69623306T2 (de) Pyrimidinderivate als 5ht2c-rezeptorantagonisten
DE69908173T2 (de) Crf rezeptor-antagonisten und darauf bezogene methoden
DE69527438T2 (de) Verbindungen zur hemmung der ceramid vermittelten signalübertragung
EP0682027A1 (de) Pyrrolopyrimidinderivate mit antiproliferativer Wirkung
DE60218434T2 (de) 4-(2-BUTYLAMINO)-2,7-DIMETHYL-8-(2-METHYL-6-METHOXYPYRID-3-YL) PYRAZOLO- 1,5-Aö-1,3,5-TRIAZIN, SEINE ENANTIOMEREN UND PHARMAZEUTISCH ANNEHMBARE SALZE ALS CORTICOTROPIN-RELEASING-FACTOR-REZEPTOR-LIGANDEN
DE69912153T2 (de) 1h-imidazo[4,5-d]pyridazin-7-one, 3h-imidazo[4,5-c]pyridin-4-one und korrespondierende thione als corticotropin freisetzende factor-(crf)-receptorliganden
DE60101372T2 (de) Pyrimidinverbindungen und ihre verwendung als modulatoren der chemokin-rezeptor-aktivität
DE60126134T2 (de) CRF-Rezeptorantagonisten und Verfahren, die damit in Beziehung stehen
DE3343922A1 (de) Gewisse substituierte pyrazolochinoline, verfahren zu ihrer herstellung, pharmazeutische praeparate enthaltend diese verbindungen und ihre therapeutische anwendung
DE60215637T2 (de) Tri- und tetraaza-acenaphthylen-derivate als crf-rezeptor-antagonisten
EP0014470A2 (de) Benzazepin-Derivate, Verfahren und Zwischenprodukte zu deren Herstellung, deren Verwendung sowie diese enthaltende Arzneimittel
DE69824195T2 (de) Dipyridoimidazolderivate zur behandlung von störungen des zentralen nervensystems
DE69927997T2 (de) Neuartige pyrimidin-derivate und verfahren zu ihrer herstellung
DE60102231T2 (de) Crf rezeptor-antagonisten und darauf bezogene methoden
DE68905363T2 (de) Heterotetracyclische laktamderivate, verfahren zu ihrer herstellung und pharmazeutische zubereitungen, die sie enthalten.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: NEUROCRINE BIOSCIENCES, INC., SAN DIEGO, CALIF., U

8339 Ceased/non-payment of the annual fee